Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trump Slams FDA Regulations In Joint Session Of Congress

Executive Summary

US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.


Related Content

Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments
FDA Soliciting Broad Range Of Comments From Industry On Regulatory Reform
Can The FDA Climate Be Too Good?
FDA Safety Initiatives Could Suffer Under Trump's Budget Proposal
Time For Big Pharma To Take Back Orphan Drugs
US FDA’s Bipartisan Support May Offer Shelter From Political Winds, Former Chief Says
US FDA Likely Not 'Significant', Could Be Mostly Spared From Trump's Regulation-Slashing Order
US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb
Trump Promises Changes To 'A Lot Of Rules' At US FDA
EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts